VERU director reports 6,000 stock options at $3.89 strike
Veru Inc. (VERU) director reports stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Veru Inc. (VERU) director reports stock option grant. On 10/01/2025, the reporting person acquired an option to purchase 6,000 shares of common stock at an exercise price of $3.89 per share. The option expires on 10/01/2035. One-third of the shares vest on each of 10/01/2026, 10/01/2027, and 10/01/2028. Following the transaction, 6,000 derivative securities were beneficially owned, held directly. The option was reported at a price of $0, indicating an award rather than an open-market purchase.
Insights
Routine director option grant with time-based vesting.
This filing discloses a standard equity award: an option for 6,000 shares at an exercise price of $3.89, granted on 10/01/2025 and expiring on 10/01/2035. The price of the derivative is listed as $0, which aligns with a compensatory grant.
Vesting is time-based: one-third on each of 10/01/2026, 10/01/2027, and 10/01/2028. This staggers potential share delivery over three years and ties realization to continued service.
As of this report, 6,000 derivative securities are beneficially owned directly. No sale methods or cash proceeds are involved here; any future value depends on the market price relative to the $3.89 strike.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock Option | 6,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options for one-third of the shares vest on each of October 1, 2026, October 1, 2027 and October 1, 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.